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Summary Four Ge(IV)-octabutoxy-phthalocyanines (GePcs) bearing two alkyl-type axial ligands were
assayed for their pharmacokinetic properties and phototherapeutic efficiency in Balb/c mice bearing an
intramuscularly transplanted MS-2 fibrosarcoma. The GePcs were i.v. injected at a dose of 0.351imolkg-'
body weight after incorporation into either Cremophor emulsions or small unilamellar liposomes of
dipalmitoyl-phosphatidylcholine (DPPC). Both the nature of the delivery system and the chemical structure of
the phthalocyanine were found to affect the behaviour of the GePcs in vivo. Thus, Cremophor-administered
GePcs invariably yielded a more prolonged serum retention and a larger association with low-density
lipoproteins (LDLs) as compared with the corresponding liposome-delivered phthalocyanines. This led to a
greater efficiency and selectivity of tumour targeting. These effects were more pronounced for those GePcs
having relatively long alkyl chains (hexyl to decyl) in the axial ligands. Maximal tumour accumulation
(0.67 nmol per g of tissue) was found for Ge-Pc(hexyl)2 at 24 h after injection. Consistently, the Ge-Pc(hexyl)2,
administered via Cremophor, showed the highest phototherapeutic activity towards the MS-2 fibrosarcoma.
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The search for second-generation tumour localisers and
photosensitisers which could enhance the efficacy and widen
the scope of photodynamic therapy (PDT) is a very active
area of research. Although many such photosensitisers have
been proposed (Moan and Berg, 1992), and some have been
introduced in phase I/II clinical trials (Dougherty, 1993), the
physicochemical and biological factors which control the
efficiency and selectivity of tumour targeting are only par-
tially understood. In vitro and in vivo studies with
haematoporphyrin derivatives etherified at the secondary
hydroxyl function with alcohols having alkyl chains of
different length (Evensen et al., 1987), as well as with meso-
substituted porphines (Berg et al., 1992) or phthalocyanines
(Chan et al., 1990) bearing 1-4 sulphonate substituents,
indicate that the affinity of the photosensitiser for malignant
cells in a variety of experimental tumours increases
with increasing hydrophobicity of the molecule. The polarity
of polycyclic photosensitisers influences their partitioning
among serum proteins (Kongshaug, 1992), as well as among
the various compartments of a tumour tissue (Henderson and
Bellnier, 1989; Korbelik, 1993).
Recently, we proposed the use of axial ligands as a tool to
modulate the degree of hydro- or lipophilicity of por-
phyrinoid compounds (Bellemo et al., 1992). Such ligands
can be readily inserted into the fifth and sixth coordinative
positions of the metal ion bound to the tetrapyrrolic mac-
rocycle, thus providing new possibilities for studying the
structure-activity relationships, besides avoiding the use of
laborious procedures for the isolation of one peripherally
substituted derivative, especially in those cases when several
positional isomers can be formed.
In this paper, we report our findings on the modalities of
in vivo transport, tissue distribution and phototherapeutic
properties of four axially substituted Ge(IV)-octabutoxy-
phthalocyanines (GePcs; see Figure 1). Previous studies from
our laboratories showed that octabutoxy-phthalocyanines
have a high quantum yield for singlet oxygen generation
(Rihter et al., 1990); in particular, GePc-Hex was shown to
be an efficient PDT agent (Cuomo et al., 1991). Moreover,
GePcs can be photoactivated by newly developed diode lasers
which are characterised by relatively high emitted power in
the far-red spectral region (Pratesi, 1984).
Materials and methods
Phthalocyanines
All GePcs were synthesised according to the general
procedure described previously (Rihter et al., 1990). The
concentration of the GePc solutions was determined spectro-
photometrically in tetrahydrofuran by using extinction
coefficients at 760 nm of 233 000 M-'cm-' for GePc-OAc,
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Figure 1 Chemical structures of GePcs.
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GePc-Hex and GePc-Dec and 246 000 M-' cm' for GePc-Et.
The incorporation of GePcs into the phospholipid bilayer of
small unilamellar vesicles of DL-a-dipalmitoyl-phosphatidyl-
choline (DPPC, Sigma, 99% pure) was achieved by a
modification of the ethanol injection procedure of Kremer et
al. (1977).
Typically, 0.75 ml of an ethanol-tetrahydrofuran solution
(1:1 v/v), which was 9.56 mM in DPPC and 0.27 mM in
GePc, were injected into 10 ml of 0.9% aqueous sodium
chloride at 55°C. For incorporation into Cremophor EL
emulsion, we followed the procedure described by Morgan et
al. (1987). Typically 1.5 mg of GePc was added to 0.3 ml of
Cremophor EL (Sigma) and sonicated until the phthalo-
cyanine was completely dispersed; then 0.09 mil of absolute
ethanol was added and resonicated. The suspension was
taken to a volume of 7.5 ml by stepwise addition of
physiological solution, filtered through 0.45 gm filters and the
GePc incorporation yield was measured at the spect-
rophotometer. All other chemicals and solvents were
analytical grade reagents.
Animals and tumour
Female Balb/c mice (20-22 g body weight) were supplied by
Charles River (Como, Italy) and kept in standard cages with
free access to tap water and standard dietary chow. Animal
care was performed according to the guidelines established
by the Italian Committee for Experimental Animals.
For tumour implantation, 2 x 10 cells of MS-2 fibrosar-
coma were suspended in 0.2 ml of sterile physiological solu-
tion and intramuscularly injected into the right hind leg of
the mouse.
All pharmacokinetic and phototherapeutic studies were
carried out on the seventh day after transplantation, when
the external tumour diameter was about 0.7 cm. When neces-
sary, the mice were anaesthetised by i.p. injection of ketalar
(150 mg kg-'). The tumour underwent no spontaneous remis-
sion.
Pharmacokinetic studies
Both healthy and tumour-bearing mice were i.v. injected with
GePc in DPPC liposomes or Cremophor emulsion at a dose
of 0.35pmolkg-' body weight. At predetermined times
between 3 h and 1 week post injection, the tumour-bearing
mice were sacrificed by prolonged exposure to ether vapours.
The GePc content was determined in serum, liver, spleen,
skin, muscle (peritumoral tissue) and tumour by chemical
extraction with tetrahydrofuran from a tissue homogenate or
a serum dilution into 2% aqueous sodium dodecyl sulphate
(SDS) according to the procedure previously described
(Cuomo et al., 1990). The GePc solution was analysed at the
spectrophotofluorimeter (Perkin Elmer MPF4, excitation at
690 nm, fluorescence collected between 720 and 880 nm) and
the fluorescence intensity was converted into phthalocyanine
concentration by interpolation with a calibration plot.
The recovery of GePc from liver and spleen was also
determined in healthy Balb/c mice at 24 h, 1 week and 4
weeks after phthalocyanine injection (0.35lmol kg-').
Plasmaprotein distribution ofGePcs
The distribution of the various GePcs among the different
serum proteins was studied at 24 h after i.v. injection of
0.35gmol kg-' in DPPC liposomes or Cremophor emulsions
by means of discontinuous density-gradient ultracentrifuga-
tion.
Typically, 2 ml of pooled plasma from eight mice was
added to potassium bromide (0.77 g), sucrose (0.05 g) and
ethylene glycol (0.2 ml). The sample (d= 1.25 gml-') was
placed in a centrifuge tube and overlayered with 2 ml of a
salt solution at d = 1.225 g tnl- (11.42 mgml-' sodium
chloride and 315.54 mgml-' potassium bromide), 3.5 ml of a
salt solution at d = 1.10gml' (11.42mgml' sodium
chloride and 133.48 mg ml-' potassium bromide), and 3.7 ml
of distilled water. The salt solutions also contained
0.1 mgml-' EDTA. For each sample, a tube containing 2 ml
of serum prestained with Sudan black was centrifuged and
used as a control for lipoprotein visualisation.
The tubes weremcentrifuged for 22 h at 39 000 r.p.m. and at
20°C in a Kontron T-2060 ultracentrifuge using a SW-41
swinging-bucket rotor (Beckman). The following fractions
were sequentially isolated from the top of the tube: very
low-density lipoproteins (VLDLs, fraction 1), low-density
lipoproteins (LDLs, fraction 2), Cremophor with unbound
GePcs (fraction 3), high-density lipoproteins (HDLs, fraction
4), heavy proteins, including mainly albumin and globulins
(fraction 5). The identification ofthe fractions was performed
as described elsewhere (Terpstra et al., 1981). The volume of
each fraction was measured, then the fractions were dialysed
overnight against physiological solution, diluted with a
binary solvent mixture (0.4ml of 4% aqueous SDS plus
1.5 ml of tetrahydrofuran) and the GePc content was deter-
mined using the spectrophotofluorimeter.
Experimentalphotodynamic therapy
For experimental PDT we used tumour-bearing mice at 24 h
after injection of 0.35gAmol kg-l GePcs in Cremophor emul-
sion. The tumour area was exposed to 776 nm light from a
diode laser (Sony), which was operated at a fluence of
180 mW cm-2. The laser emission was coupled into a 600gm
optical fibre, whose tip was placed at a distance from the
tumour surface yielding an illuminated area of 0.5 cm2. The
overall delivered light dose was 300 J cm-2.
The development of the necrotic area was measured as a
function of time after the end of irradiation. The procedure
involved the fixation of the excised tumour in 10% formalin
followed by sectioning of the tumour at 1 mm intervals. The
width and depth of the necrotic area were measured for each
tissue slice as previously described (Reddi et al., 1990).
Results
A typical absorption spectrum of GePcs in DPPC liposomes
and Cremophor emulsions is shown in Figure 2; the position
of the maxima undergoes only minor shifts for the individual
compounds. The spectrum of GePcs in Cremophor is essen-
tially identical to the spectrum in a tetrahydrofuran solution,
in which the phthalocyanines are completely monomeric,
since there is a linear relationship between the maximum
absorbance and the dye concentration. On the other hand, it
is likely that some aggregation occurs upon incorporation of
GePcs into DPPC liposomes; as shown in Figure 2, in these
phospholipid vesicles, the absorption spectra of phthalo-
cyanines are broadened, with significant hypochromicity of
the band peaking around 760 nm. The hypochromicity ofthe
680 nm band is less pronounced; consequently the ratio
between the two absorption maxima has been proposed as a
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Figure 2 Absorption spectrum of 12iLM GePc-Hex in DPPC
liposomes (-00) and in Cremophor EL emulsion (-).
I
, ," -.- I I I Iparameter for evaluating the monomeric index, i.e. an
indicator of the aggregation state of the phthalocyanine
(Segalla et al., 1994). As can be seen from Table I, for all
GePcs such a ratio is very close to that observed in tetrahyd-
rofuran when the phthalocyanines are incorporated into
Cremophor, whereas the ratio is lower when the GePcs are
embedded into DPPC liposomes. The lowering is particularly
evident for GePc-OAc and GePc-Et and is accompanied,
respectively, by a c. 25 nm and 15 nm red shift of the absorp-
tion bands.
The concentration of the intravenously injected GePcs in
the serum at 3 h and 24 h is shown in Table II. With either
delivery system more than 90% of the GePcs become
associated to the serum lipoproteins, as indicated by studies
of serum distribution at 24h after administration (Table III).
Clearly, DPPC liposomes appear to favour the binding of
GePcs to HDLs, while Cremophor micelles increase the
amount of phthalocyanine bound to LDL. The amount of
LDL-bound dye is especially high for the Cremophor-
delivered GePcs bearing purely alkyl axial ligands.
The histograms in Figure 3 show the accumulation in the
MS-2 fibrosarcoma at different times after administration of
DPPC liposome-delivered GePcs. In general, the phthalo-'
cyanine concentration in the tumour is highest around 24 h,
followed by a gradual decline until at least 1 week post
injection. Only in the case of GePc-OAc is the amount
recovered essentially constant throughout the 3-48 h inter-
TableI Ratiobetweentheabsorbancesofthebandaround760 nm(Al)
and 680 nm (A2)forGe(IV)-octabutoxy-phthalocyanines in tetrahydro-
furansolution orincorporated into DPPC liposomes orCremophorEL
micelles. Phthalocyanine concentration was in the 5-7gM range
Tetrahydrofuran DPPC Cremophor
Drug Al/A2 Al/A2 )IIA2
GePc-OAc 4.5 3.0 4.2
GePc-Et 4.6 3.1 4.2
GePc-Hex 4.8 3.7 4.4
GePc-Dec 4.7 4.0 4.5
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val. Very similar data were obtained in pharmacokinetic
studies with Cremophor-delivered GePcs (Figure 4); however,
in this case, consistently larger tumour concentrations of the
four phthalocyanines were obtained.
We also analysed the amount of GePcs localised in the
skin, which could induce a general cutaneous photosen-
sitivity, and the muscle, that is the peritumoral tissue in our
animal model. In all cases, the recoveries of GePcs from
these tissues were markedly lower than from tumour. The
tumour/muscle and tumour/skin ratios of GePcs concentra-
tion at 24 h post injection, i.e. when the tumour accumula-
tion is maximal, are summarised in Table IV. Apparently,
Cremophor delivery induces a more selective tumour
targeting with all the four GePcs.
Lastly, we found a large accumulation of the phthalo-
cyanines by some components of the reticuloendothelial
system, with maximal recoveries of 3-4 nmol g'- in liver and
2-3 nmol g-' in spleen. This is typical of dyes delivered via
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Figure 3 Time dependence of GePc recovery from MS-2
fibrosarcoma (average of five mice). GePcs were incorporated in
DPPC liposomes and i.v. injected at a dose 0.35 1smol kg-'. E:l,
GePc-OAc; E1, GePc-Et; -, GePc-Hex; *, GePc-Dec.
Table H Concentrations (nmol ml-') of GePcs in the serum of
tumour-bearing mice at 3 h and 24 h after i.v. injection of
0.35pmol kg- phthalocyanine in DPPC liposomes or Cremophor EL
micelles. Five mice per group
Delivery 3 h 24 h
Drug system (mean ± s.d.) (mean ± s.d.)
GePc-OAc DPPC 0.89 + 0.15 0.06± 0.01
Cremophor 2.40 0.19 0.11 0.03
GePc-Et DPPC 0.11 ± 0.01 0.08 ± 0.03
Cremophor 3.42 ± 0.32 0.20 ± 0.09
GePc-Hex DPPC 0.11 + 0.01 0.08 ± 0.04
Cremophor 4.37 + 0.68 1.03 i 0.40
GePc-Dec DPPC 0.58 ± 0.09 0.02 ± 0.00
Cremophor 3.67 + 0.38 0.37 ± 0.01
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Figure 4 Time dependence of GePc recovery from MS-2
fibrosarcoma (average offive mice). GePcs were incorporated in a
Cremophor EL emulsion and i.v. injected at a dose 0.35 lmol
kg-'. See Figure 3 for key.
Table III Distribution (percentage of total recovery) of GePcs among ultracentrifugally separated protein
fractions obtained from mouse plasma at 24 h after i.v. injection of0.35jimolkg-' phthalocyanine in DPPC
liposomes or Cremophor EL micelles (CR-EL). Average ± s.d. of three experiments
Delivery Heavy
Drug system VLDL (%) LDL (%) HDL (%) proteins (%) CR-EL (%)
GePc-OAc DPPC 22.1 6.8 24.8 3.5 46.1 ± 3.61 8.0± 7.1
Cremophor 25.4 0.3 35.3 ± 1.0 35.3 ± 0.49 ND" 4.0 0.7
GePc-Et DPPC 20.3 ± 2.1 29.5 ± 2.1 45.2 ± 5.75 5.0 ± 4.6
Cremophor 17.3 ±4.2 47.8 4.1 28.2 3.96 NDa 6.7 ± 1.4
GePc-Hex DPPC 6.7 ± 5.6 35.7 ± 7.1 55.2 ± 8.20 2.4 ± 8.2
Cremophor 4.4 + 3.1 44.3 ± 2.3 45.6 + 0.78 2.3 + 1.6 6.3 ± 0.6
GePc-Dec DPPC 2.7 + 0.2b 16.6± 8.3b 74.8 ± 12.2b 6.1 ± 3.7b
Cremophor 7.2c 46.9 ± 6.8 29.9 ± 7.1 3.9 ± 2.7 15.4± 6.9
aNot detectable. bOnly two experiments. cOnly one determination.
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lipid-type vehicles (Scherphof et al., 1989). In order to study
the rate of GePc clearance from these organs, we extended
our pharmacokinetic investigations to healthy mice, since no
reliable pharmacokinetic data could be obtained with
tumour-bearing mice beyond 1 week owing to the fast
growth of the fibrosarcoma. The data shown in Table V
indicate an extensive decrease in the phthalocyanine concen-
tration at 4 weeks post injection.
On the basis of the biodistribution studies, PDT experi-
ments were carried out at 24 h after administration of
0.35ftmol kg-l of the GePcs bearing hydrocarbon ligands in
Cremophor emulsions, namely those displaying the largest
affinity for our tumour model. The development of tumour
necrosis as a function of post-irradiation time is com-
paratively shown in Figure 5.
Discussion
Our findings clearly indicate that octabutoxy-GePcs bearing
siloxyalkyl axial ligands on the metal ion represent an attrac-
tive class of photosensitisers for use in the PDT of tumours.
These compounds can be readily prepared by chemical syn-
thesis with a high degree ofpurity (Sounik et al., 1990), while
the possibility of introducing axial substituents with different
levels of hydro/lipophilicity and steric hindrance allows a
large flexibility in the determination of the physicochemical
properties of the photosensitiser, which in turn markedly
influence its behaviour in vivolJori, 1989). Besides favourable
spectroscopic and photophysical characteristics (Ford et al.,
1989), GePcs can exhibit an appreciable affinity for tumours,
as well as a good phototherapeutic activity provided the
delivery system and the chemical structure of the photosen-
sitiser are properly chosen.
Actually, in all cases, Cremophor-administered GePcs
exhibited greater and more selective tumour targeting as
Table IV Ratio between the tumour/muscle and tumour/skin
concentration of GePcs at 24 h after injection of 0.35gmolkg-'
phthalocyanine in DPPC liposomes or Cremophor EL micelles.
Average offive mice ± s.d.
Delivery Twnour/ Tumour/
Drug system muscle skin
GePc-OAc DPPC 2.61 ± 0.69 2.86 ± 0.70
Cremophor 5.68 ± 0.98 8.64 ± 1.34
GePc-Et DPPC 2.20 ± 0.23 2.47 ± 0.21
Cremophor 7.37 1.47 4.93 1.11
GePc-Hex DPPC 5.40 1.01 2.98 +0.65
Cremophor 8.48 ± 1.70 11.63 ± 1.84
GePc-Dec DPPC 6.26 ± 0.42 3.40 ± 0.55
Cremophor 11.81 ± 2.91 4.79 + 1.55
compared with the corresponding phthalocyanines adminis-
tered via DPPC liposomes (Figures 3 and 4, Table IV). Our
serum distribution and pharmacokinetic data suggest two
possible explanations for this observation.
(i) As can be seen from Table II, Cremophor-delivered
GePcs are cleared from the serum more slowly than
DPPC-delivered GePcs; at 24 h post injection the
phthalocyanines are almost exclusively bound to
serum lipoproteins, but a small amount is still
retained by the Cremophor micelles. Previous in vitro
studies showed that the photosensitiser release to
lipoproteins by the Cremophor emulsion is a slow
process, hence lipoproteins could act as a reserve pool
for the sustained release of the associated photosen-
sitiser to tumour.
(ii) Cremophor-delivered GePcs are complexed in larger
amounts with LDLs (Table III), which are known to
develop a preferential interaction with several tumour
types (Maziere et al., 1991). Therefore, the present
findings would support the proposal that LDLs play a
role in the transport and release of hydrophobic
photosensitising agents to those tumours exhibiting
high LDL receptor activity, such as the fibrosarcoma
used in the present investigation (Lombardi et al.,
1989).
An LDL-orientating action of Cremophor has been
previously reported for Sn(IV)-etiopurpurin administered to
rabbit plasma (Polo et a/., 1992). The mechanisms underlying
this effect are not apparent, although they are probably
related to the modality of interaction between the individual
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Figure 5 Extent of tumour necrosis at different times after
irradiation of the MS-2 fibrosarcoma in mice exposed to 776 nm
light (180mWcm-2, 300Jcm-2) at 24h after i.v. injection of
0.35 zmol kg-' GePc-Et (-U-), GePc-Hex (-*-), or GePc-
Dec (-A-) incorporated in Cremophor EL micelles (means +
s.d.).
TableV Recoveries (nmol g-' tissue) ofGePcs fromliverand spleenofhealthyBalb/c
mice at different times after injection of 0.35pmolkg-' phthalocyanine in DPPC
liposomes or Cremophor EL micelles. Average offive mice
Liver Spleen
Drug Time DPPC Cremophor DPPC Cremophor
GePc-OAc 24h 3.57±0.53 3.71 0.32 1.53±0.18 1.93±0.34
1 week 1.92±0.40 2.10±0.23 0.73±0.10 0.65±0.18
4 weeks 0.26 ± 0.06 0.13 ± 0.09 0.16 _ 0.02 0.14± 0.02
GePc-Et 24 h 2.25 _ 0.24 6.00± 0.37 2.12± 0.92 2.36± 0.19
1 week 1.52 0.24 3.73 0.06 0.66 0.06 1.92 0.06
4 weeks 0.43 ± 0.06 0.67 0.04 0.37 ± 0.06 0.63 ± 0.06
GePc-Hex 24 h 4.42± 0.82 3.70± 0.49 1.90 ± 0.62 2.43 ± 0.33
1 week 2.02 0.26 2.73 0.60 1.07 0.28 1.64± 0.05
4 weeks 0.39 _ 0.07 0.05 _ 0.01 0.07 _ 0.01 0.64± 0.05
GePc-Deca 24 h 3.19 0.06 2.21 0.20 0.83 0.06 1.13 ± 0.01
I week 2.22 0.14 0.05 0.01 0.62 0.02 0.18 ± 0.05
4 weeks ND"b NDb NDb NDb
aData obtained with tumour-bearing mice. bNot determined.
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lipoprotein classes and the lipophilic vehicle. Thus,
Cremophor has been found to alter the density of lipo-
proteins (Kongshaug et al., 1991), indicating that at least a
partial fusion between the oil emulsion and the lipid moiety
of the phospholipid bilayer of the lipoproteins must occur.
Similarly, the fluidity and composition of the phospholipid
bilayer of liposomal vesicles influences both the interlipo-
protein distribution of phthalocyanines and the kinetics of
photosensitiser release to lipoproteins (L Polo, E Reddi and
G Jori, unpublished observations).
In any case, the selectivity of tumour targeting, as
expressed by the ratio between the photosensitiser concentra-
tion in the tumour and peritumoral tissue (Table IV), is
clearly larger for GePcs with longer hydrocarbon chains,
which presumably have a higher level of hydrophobicity.
Since the amount ofGePc recovered from the tumour at 24 h
is fairly similar for the four phthalocyanines examined by us
(Figures 3 and 4), the observed effect mainly reflects a lower
accumulation of the drugs by the muscle. In general, the
muscle takes up small amounts of photosensitisers and, as a
consequence, tumour/peritumoral tissue ratios are higher for
intramuscularly implanted tumours than those for tumours
implanted in other anatomical sites with the exception of
brain tumours (Tralau et al., 1987). However, the levels of
selectivity thus reached are at least similar to those found for
other second-generation photosensitisers delivered in lipo-
somes and tested in the same tumour model (Reddi et al.,
1990; Segalla et al., 1994) and markedly larger than that
typical of Photofrin (Dougherty, 1987). A similar enhance-
ment of the tumour-localising efficiency has been observed
upon lowering the number of sulphonate substituents in the
peripheral positions of the phthalocyanine macrocycle
(Korbelik, 1993); less polar phthalocyanines are endowed
with a higher tendency to penetrate malignant cells, thereby
shifting the mechanism of photoinduced tumour necrosis
from a prevailing vascular damage to a direct inactivation of
neoplastic cells (Milanesi et al., 1987; Henderson and Bell-
nier, 1989).
All GePcs are accumulated in large amounts by liver and
spleen, independently of the delivery system used for their
administration (Table V). This suggests that the phthalo-
cyanines are predominantly eliminated from the organism via
the bile-gut pathway, as already found for several liposome-
bound photosensitisers (Jori, 1987). However, the overall
clearance of the GePcs from liver occurs remarkably faster
than the clearance of Photofrin II (Bellnier et al., 1989) or
Zn(II)-phthalocyanine (Reddi et al., 1990), in which cases
significant residual amounts of dye are reovered at 4 weeks
after injection. It has been proposed that the slow elimination
of these compounds is due to the presence of aggregated
material for which lymphatic drainage would be very
inefficient (Isele et al., 1995). Our results do not support this
hypothesis since we observed no significant difference in the
disappearance rate for GePcs delivered via Cremophor, in
which they are essentially monomeric, or DPPC liposomes, in
which some degree of aggregation is likely to occur (Table I).
However, we cannot rule out the possibility that the
aggregated fraction of GePcs undergoes monomerisation in
the serum.
All the three Cremophor-delivered GePcs tested for their
phototherapeutic activity in our animal model induce a fast-
developing tumour necrosis, which reaches its maximal exten-
sion at c. 6 h post irradiation. The therapeutic efficiency is
similar to that observed for the unsubstituted Zn-phthalo-
cyanine (Reddi et al., 1990), but higher than that observed
for other phthalocyanine derivatives (Segalla et al., 1994)
tested in the same tumour model. The higher PDT efficiency
exhibited by the bis(siloxyhexyl)derivative may reflect the
slightly larger concentration of this GePc in the tumour at
the time of irradiation.
A direct relationship between the tumour concentration of
the photosensitiser and the extension of the tumour necrosis
has been observed in the case of unsubstituted Zn(II)-
phthalocyanine (Reddi et al., 1990).
On the basis of these findings, it appears important to
extend our pharmacokinetic and tumour photosensitisation
studies in order to gain more detailed information on the
affinity of the individual GePcs for the most important heal-
thy tissues, as well as to refine the phototherapeutic pro-
tocols.
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